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Abstract
Background: Previous experiments have shown that a decoction of Bauhinia forficata leaves
reduces the changes in carbohydrate and protein metabolism that occur in rats with
streptozotocin-induced diabetes. In the present investigation, the serum activities of enzymes
known to be reliable toxicity markers were monitored in normal and streptozotocin-diabetic rats
to discover whether the use of B. forficata decoction has toxic effects on liver, muscle or pancreas
tissue or on renal microcirculation.
Methods: An experimental group of normal and streptozotocin-diabetic rats received an aqueous
decoction of fresh B. forficata leaves (150 g/L) by mouth for 33 days while a control group of normal
and diabetic rats received water for the same length of time. The serum activity of the toxicity
markers lactate dehydrogenase, creatine kinase, amylase, angiotensin-converting enzyme and
bilirubin were assayed before receiving B. forficata decoction and on day 19 and 33 of treatment.
Results: The toxicity markers in normal and diabetic rats were not altered by the diabetes itself
nor by treatment with decoction. Whether or not they received B. forficata decoction the normal
rats showed a significant increase in serum amylase activity during the experimental period while
there was a tendency for the diabetic rats, both treated and untreated with decoction, to have
lower serum amylase activities than the normal rats.
Conclusions: Administration of an aqueous decoction of B. forficata is a potential treatment for
diabetes and does not produce toxic effects measurable with the enzyme markers used in our
study.
Background
The tree Bauhinia forficata is a member of the Brazil-wood
family (Caesalpiniaceae) [1] commonly known in Brazil
as "Pata de Vaca" or "Unha de Vaca" (cow's hoof) and the
USA as the "Brazilian orchid-tree". Phytochemical
research has revealed that this plant contains alkaloids,
tannins, mucilage, essential oil, cyanogenetic heteroglyco-
sides, anthocyanins, saponins, catechols and fixed volatile
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acids [2,3]. In Brazil, B. forficata is one of the most fre-
quently used anti-diabetic herbal remedies and we have
shown [4] that administration of an aqueous decoction of
fresh B. forficata leaves to streptozotocin-diabetic rats for a
month lowered the levels of serum and urinary glucose
and urinary urea in comparison to diabetic rats which had
not received decoction.
Plants can, however, have toxic side-effects [5,6] and
because nothing has been published on the toxicity of B.
forficata we tested orally administered B. forficata decoc-
tion for its effects on the toxicity markers amylase (pan-
creas toxicity), creatine kinase (muscle toxicity), lactate
dehydrogenase (muscle and liver toxicity), bilirubin (liver
and biliary toxicity) and angiotensin-converting enzyme
(renal microcirculation and kidney toxicity).
Methods
Decoction preparation
Material from a B. forficata tree in the Medicinal Plants
Garden of the School of Pharmacy, Araraquara, São Paulo
State, Brazil was identified, authenticated and deposited
in the Herbarium of the Department of Industrial Phar-
macy, Federal University of Santa Maria, Rio Grande do
Sul, Brazil, as accession no. 119, by Dr. Gilberto Dolejal
Zanetti. Leaves were collected from this tree between April
and May and a decoction prepared by the method nor-
mally used in the Araraquara region, i.e. boiling 150 g of
fresh leaves in a litre of water for 5 minutes, allowing the
decoction to stand for 30 minutes and filtering it through
a paper filter, the final yield of filtrate being 87% v/v. The
decoction was prepared every 2 or 3 days and kept in
brown-glass bottles at 4°C.
Animals and their treatment
All rats were fed a normal laboratory chow diet containing
(wt/wt) 16% protein, 66% carbohydrate and 8% fat and
were housed under a 12:12 h light and dark cycle at 22–
25°C. The experimental protocols and the treatment and
care of the rats followed the rules of the Brazilian ethics
committees [7].
A group of 50 male Wistar rats were allowed to adapt to
metabolic cages for 2 days and then deprived of food for
14–16 h and weighed [mean body weight (bw) = 129.5 ±
1.2 g] and anaesthetised with ethyl ether. Thirty of the rats
were randomly selected and diabetes induced in them by
injecting a solution of streptozotocin (50 mg/kg bw dis-
solved in 0.01 M citrate buffer, pH 4.5) into the jugular
vein of each rat, the remaining 20 rats being injected with
0.9 % saline by the same route, these being denominated
'normal rats'. All rats were then returned to their meta-
bolic cages where they had free access to food and water.
Decoction administration and sampling procedures
Four days after streptozotocin injection the 30 diabetic
rats were assessed for body weight, food and liquid intake,
urinary glucose and urea, and (using tail-tip blood)
plasma glucose and serum bilirubin and amylase, creatine
kinase, lactate dehydrogenase and angiotensin-converting
enzyme activities. Ten pairs of rats with diabetes of a sim-
ilar degree of severity were selected from the 30 diabetic
rats by matching their body weight, plasma glucose level
and urinary glucose and urea excretion as closely as possi-
ble. One diabetic rat from each pair was randomly
assigned to the diabetic-treated (DT) group (n = 10) and
received B. forficata decoction freely in place of drinking-
water while the other diabetic rat was assigned to the dia-
betic-control (DC) group (n = 10) and had free access to
drinking-water. The remaining 10 diabetic rats could not
be closely matched and were not used. The 20 normal rats
were assessed for body weight and serum amylase, creat-
ine kinase, lactate dehydrogenase and angiotensin-con-
verting enzyme activities. Ten of the 20 normal rats were
randomly assigned to the normal-treated (NT) group (n =
10) and received B. forficata decoction freely in place of
drinking-water while the other 10 received drinking-water
and constituted the normal-control (NC) group (n = 10).
All four groups received water for the first six days after
streptozotocin injection, after which the water in the met-
abolic cages of the diabetic-treated and normal-treated
groups was replaced by decoction while the rats in the dia-
betic-control and normal-control groups continued to
have access to plain water.
Twenty-five days after injection with streptozotocin or
saline and 19 days after being given access to decoction
the rats were weighed and their serum enzyme activities
measured. Thirty-nine days after injection with streptozo-
tocin or saline and 33 days after being given access to
decoction the total volume of decoction or water con-
sumed was calculated for each rat and the rats weighed
and then sacrificed at between 8:00–9:30 am by decapita-
tion and samples of the free-running blood collected and
the serum enzyme activities and bilirubin determined.
Two hours before sacrifice, blood samples were collected
from the tail of each rat and used to determine serum cre-
atine kinase activity.
Blood samples for plasma glucose determination were
collected in Eppendorf tubes containing liquaemin
sodium which were cooled in ice for 30 minutes and then
centrifuged at 1000 × g for 10 minutes and the serum sep-
arated. Blood samples for serum enzyme assay were col-
lected in gel separator tubes (Becton-Dickinson) and the
serum separated by centrifuging at 1000 × g for 10 min-
utes. Serum angiotensin-converting enzyme activity and
urinary glucose and urea were measured up to 30 days
after collection of the samples, which were stored at -20°C
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until assayed. Lactate dehydrogenase activity was meas-
ured within 4 days of collection using serum stored at
25°C and creatine kinase activities within 7 days from
serum stored at -20°C. Plasma glucose, serum bilirubin
and amylase were measured immediately after blood col-
lection. All analyses were made on the same day in groups
of 10 samples.
Biochemical analyses
Urinary glucose was measured by the o-toluidine method
of Duboswski [8] and urea by the urease method [9,10].
Plasma glucose was determined in a Bayer Technicon RA-
XT autoanalyser. Colorimetric methods were used to
measure lactate dehydrogenase [11] and amylase activity
[12] and the total serum bilirubin concentration was
measured using an unconjugated indirect assay [13] and a
glucuronic acid conjugated direct assay [14]. Creatine
kinase [15] and angiotensin-converting enzyme [16]
activities were measured by kinetic spectrophotometric
methods. All assays were performed using an Hitachi U
1100 spectrophotometer. Reagents were purchased from
Merck or Sigma and were of at least analytical grade and
the sample storage times and temperatures rigorously
controlled to minimise deterioration.
Statistical analysis
Means and standard errors were calculated from the data
and analysed using two-way analysis of variance
(ANOVA), the Newman-Keuls test being used for subse-
quent multiple comparisons between groups for identical
periods and over time within groups. The unpaired Stu-
dent's t-test was used to analyse the bilirubin data. The sig-
nificance level was p < 0.05.
Results
Four days after injection with streptozotocin and 2 days
before administration of decoction (time zero), the dia-
betic-treated and diabetic-control groups showed practi-
cally the same pattern of physiological and metabolic
alterations (Table 1) and there was also no difference
between any of the four groups, either at time zero (Figure
1) or throughout the 33 days of the experiment, in lactate
dehydrogenase activity.
There was no significant differences in serum bilirubin
measurements between diabetic-treated and diabetic-con-
trol groups or between these groups and the normal-
treated and normal control groups (Figure 2).
Creatine kinase activity in the four groups was similar at
time zero and remained so on the 19th and 33rd day of the
experiment, although it tended to rise gradually over the
experimental period but within each group the difference
between the initial and final activities was not significant
(Figure 3).
Amylase activity was similar in all four groups, although,
except for the diabetic-treated group on the day 33, there
was a tendency throughout the experiment towards lower
values in the two diabetic groups compared with the two
normal groups, (Figure 4). There was a significant rise in
amylase activity in both the normal groups on the day 19
and in the diabetic-treated and the two normal groups on
the day 33 relative to time zero.
Table 1: Physiological and metabolic variables for streptozotocin-diabetic rats.
Body weight (g) ∆w Liquid intake 
(ml/24 h)
Urinary volume 
(ml/24 h)
Food intake 
(g/24 h)
Plasma glucose 
(mg/dl)
Urinary glucose 
(g/24 h)
Urinary urea 
(mg/24 h)
DC 154.8 ± 2.76 26.0 ± 2.29 57.6 ± 4.05 28.6 ± 3.70 17.9 ± 0.60 369.9 ± 26.7 1.88 ± 0.28 600.2 ± 53.5
DT 154.0 ± 3.68 24.1 ± 3.52 61.3 ± 4.66 31.4 ± 3.38 18.5 ± 0.61 373.8 ± 17.9 1.95 ± 0.27 692.3 ± 41.1
DC = diabetic-control; DT = diabetic-treated; ∆w = weight-change relative to the weight on the day on which the streptozotocin was injected. All 
parameters except body weight, ∆w and plasma glucose are given per 100 g of body weight and all values are means ± standard error measured on 
the 4th day after injection with streptozotocin and before starting treatment with Bauhinia forficata decoction.
Serum levels of lactate dehydrogenase activity in normal and streptozotocin-diabetic rats during extended treatment withBauhinia forficataFig re 1
Serum levels of lactate dehydrogenase activity in 
normal and streptozotocin-diabetic rats during 
extended treatment with Bauhinia forficata. Groups: 
 normal-control; ■ diabetic-control;  normal-treated; ▲ 
diabetic-treated. All values are means ± standard error (n = 
10).
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Angiotensin-converting enzyme activity was similar both
within and between all four groups and no significant dif-
ferences was seen between diabetic and normal groups
throughout the experiment (Figure 5).
All the rats grew at similar rates throughout the experi-
ment, with the rats in both the normal groups showing
Serum levels of bilirubin of normal and streptozotocin-dia-b tic rats on day 33 of treatment with Bauhinia forfi ataFig re 2
Serum levels of bilirubin of normal and streptozo-
tocin-diabetic rats on day 33 of treatment with 
Bauhinia forficata. Groups: DC-diabetic-control; DT-dia-
betic-treated; NC- normal-control; NT-normal-treated. All 
values are means ± standard error (n = 10.)
Serum levels of creatine kinase activity in normal and strep-tozotocin-diabetic rats during extended treat ent with Bauhinia forficataFig re 3
Serum levels of creatine kinase activity in normal and 
streptozotocin-diabetic rats during extended treat-
ment with Bauhinia forficata. Groups:  normal-control; 
■ diabetic-control;  normal-treated; ▲ diabetic-treated. All 
values are means ± standard error (n = 10).
Serum levels of amylase activity in normal and streptozo-tocin-diab tic rats during extended treatme t with Bauhinia f rf cataFig re 4
Serum levels of amylase activity in normal and strep-
tozotocin-diabetic rats during extended treatment 
with Bauhinia forficata. U = amount of enzyme that com-
pletely hydrolyses 10 mg of starch in 30 min at 37°C.  nor-
mal-control; ■ diabetic-control;  normal-treated; ▲ 
diabetic-treated. All values are means ± standard error (n = 
10). A two-way ANOVA and the Newman-Keuls test was 
used for comparisons over time within groups (p < 0.05) – 
different from before start of treatment (day zero) with 
Bauhinia forficata decoction. Groups: (a) normal-control; (b) 
normal-treated; (c) normal-control; (d) normal-treated; (e) 
diabetic-treated.
Serum levels of angiotensin-converting enzyme (ACE) activity in normal and streptozotocin-diabetic rats during extended treat ent with Bauhinia f rficataFig e 5
Serum levels of angiotensin-converting enzyme 
(ACE) activity in normal and streptozotocin-diabetic 
rats during extended treatment with Bauhinia forfi-
cata.  normal-control; ■ diabetic-control;  normal-
treated; ▲ diabetic-treated. All values are means ± standard 
error (n = 10).
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considerable weight gains on both day 19 and 33 while
the diabetic rats grew more slowly and showed an insig-
nificant change between day 19 and 33 (Figure 6)
The average volume of decoction consumed up to day 33
was 54.8 ± 6.8 ml/24 h.100 g bw by rats in the diabetic-
treated group and 15.0 ± 0.5 ml/24 h.100 g bw in the nor-
mal-treated group, while average water consumption was
57.0 ± 8.2 ml/24 h.100 g bw in the diabetic-control group
and 13.4 ± 0.4 ml/24 h.100 g bw in the normal-control
group. The results were similar for the two diabetic and
two normal groups although there were statistically signif-
icant statistical differences between the diabetic-treated
and normal-treated groups and the diabetic-control and
normal control groups. The only observable effect being
the polydipsia characteristic of diabetes.
Discussion
For the results to be properly evaluated it was essential
that the diabetic-treated and diabetic-control groups
should show similar alterations in the diabetes-affected
parameters prior to treatment with B. forficata decoction,
and this is what we in fact found (Table 1).
The cytotoxicity of a xenobiotic can be evaluated using the
serum activities of marker enzymes. One such enzyme is
lactate dehydrogenase, which, though distributed
throughout the body, possesses isoenzymes recognised as
markers for liver and muscle lesions [17]. It is also well-
established that the serum level of bilirubin is raised when
the hepatic biliary system is affected [18]. We have previ-
ously observed that B. forficata leaf decoction orally
administered to diabetic rats leads to an improvement in
carbohydrate and protein metabolism [4] and since our
current research shows no change in either lactate dehy-
drogenase activities or bilirubin levels in either the
diabetic-treated or the normal-treated group (Figures 1
and 2) it appears that this improvement occurs without
damage to the liver, bile ducts or muscles. It is, however,
important to exclude the possibility that the diabetes itself
damages these tissues in such a way that serum activities
of lactate dehydrogenase and bilirubin are altered [18]
and our finding that the lactate dehydrogenase activity in
the diabetic-control group was no higher at the end of the
experiment than at time zero indicates that there was no
diabetes-induced damage in the liver, bile-ducts or
muscles and supports our previous results using the same
experimental model over a period of 53 days [19]. There
is little published data on serum lactate dehydrogenase
activity but experiments in which Tinospora cordifolia root
extracts [20] and certain Egyptian herbs [21] were admin-
istered to alloxan-induced diabetic rats indicate that dia-
betes leads to raised serum lactate dehydrogenase activity
which could be reduced treatment with insulin or plant
extracts [20,21].
Contradictory reports can be found in the literature on the
relationship between diabetes and serum creatine kinase
activity, which has been variously described as increasing
or decreasing in diabetes [22-25]. We have previously
shown [19] that under the same conditions as those
employed here the muscle changes resulting from
induced diabetes are not reflected in altered serum creat-
ine kinase activity and on this basis it appears that admin-
istration of B. forficata decoction does not enhance muscle
cytotoxicity. Our current results for creatine kinase activity
against time for the diabetic-untreated group (Figure 3)
supports our previous results [19] and the lack of any
effect of the decoction on creatine kinase activity in nor-
mal rats confirms the lack of cytotoxicity in the diabetic
groups.
Serum amylase activities in the diabetic groups (Figure 4)
supports our previous data in respect to time after strepto-
zotocin injection [19] and it appears that 33 days of treat-
ment with B. forficata decoction did not alter amylase
production in the pancreas or the saliva because serum
amylase activities in both diabetic groups were similar
both in the middle and at the end of the experiment. In
the present study we detected only a tendency for serum
amylase activities to be lower in diabetic than normal rats
throughout the experiment, such changes possibly being
due to endocrine, exocrine and paracrine changes in the
parenchyma of the pancreas [19,26,27]. In both normal
Body weight of normal and streptozotocin-diabetic rats dur-ing extended treatment with Bauhinia f rficataFi ure 6
Body weight of normal and streptozotocin-diabetic 
rats during extended treatment with Bauhinia forfi-
cata.  normal-control; ■ diabetic-control;  normal-
treated; ▲ diabetic-treated. All values are means ± standard 
error (n = 10). A two-way ANOVA and the Newman-Keuls 
test was used for comparisons over time within groups (p < 
0.05): (a) all groups – different from day zero; (b) the normal-
control and normal-treated groups different from day 19.
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groups the increased amylase activity observed during the
experiment may have been related to fluctuations in the
rates of amylase synthesis and its secretion by secretory
glands, such fluctuations having been attributed to ageing
of the animals [28-31]. The significant increase in amylase
activity in the diabetic-treated group on day 33 relative to
time zero does not necessarily indicate toxicity because
there was no significant difference between the amylase
activities of the diabetic-treated and diabetic-control
groups on day 33, and it appears that the rise in amylase
level in the diabetic-treated group on day 33 is probably
due to a random effect. The similarity in amylase activity
between the two normal groups throughout the experi-
ment supports our other findings which suggest that treat-
ment with B. forficata decoction is not toxic.
Angiotensin-converting enzyme catalyses the conversion
of angiotensin I to the vasopressor angiotensin II in lung,
renal and mesenteric vascular tissue [32,33]. Published
data have demonstrated that serum and tissue Angi-
otensin-converting enzyme activities can rise, fall or
remain the same as a result of diabetes [26,34-37]. As
reported in this paper, previous results obtained in our
laboratory showed no change in Angiotensin-converting
enzyme activity in the diabetic groups relative to the nor-
mal groups [19]. Serum angiotensin-converting enzyme
activities have been suggested as an indicator of microan-
giopathy in diabetics [38,39] and our finding that angi-
otensin-converting enzyme activities were unchanged in
the diabetic-treated group implies that treatment with B.
forficata decoction did not give rise to any increase in the
microangiopathy that may have been present in the rats
(Figure 5).
The body weight of the rats was not altered by the plant
decoction in either diabetic or normal rats relative to their
respective controls (Figure 6). These results agree with
those for the enzymatic markers and also suggest that B.
forficata decoction is not toxic. The reduced growth rate
seen in the two diabetic groups between day 19 and 33
was probably due to insulin depletion provoking loss of
adipose tissue [4].
Garg et al [40] observed that cattle fed on immature Quer-
cus incana (tender oak) leaves suffered 70% mortality and
there was extensive nephro- and hepatotoxicity due to
hydrolysable tannins and simple phenols in the leaves but
despite the presence of tannins in B. forficata [2,3] there
appeared to be no renal or hepato-biliary toxicity in the
rats because we found no change in lactate dehydrogenase
or angiotensin-converting enzyme activities or in
bilirubin levels. The concentration of tannins and other
components of B. forficata leaf decoction is still unknown
and this prevents a comparative evaluation of this extract
with other tannin containing extracts.
The serum marker assays indicate that although the B. for-
ficata decoction did not provoke any worsening of diabe-
tes-induced tissue-changes it also did not bring about any
improvement. Such findings should be quite reliable,
since they were obtained with markers (lactate
dehydrogenase, creatine kinase and angiotensin-convert-
ing enzyme activities and bilirubin levels) that are not
influenced by diabetes per se, although the data on serum
angiotensin-converting enzyme activity should be inter-
preted in the light of its inherently altered level in diabetic
animals.
On the basis of these results we conclude that Bauhinia for-
ficata leaf decoction could be of use in the treatment of
diabetes because it improves the diabetic condition
without causing tissue toxicity detectable by biomarkers
appropriate for this experimental model.
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